NOAC

Bayer Initiates Phase III Study Program for Investigational Oral FXIa Inhibitor Asundexian

Retrieved on: 
Sunday, August 28, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Cardiology, Patient, European Society of Cardiology, Safety, Trust, Program, Proper Dose, Oral, Executive Committee, MacEwen, Proper, Infarction, PMID, Ageing, Disease, Factor XI, S-1 Executive Committee, Science, American College, Xia, Lancet, American College of Cardiology, BAY, Connolly, Blood, Stroke, Nootropic, Group, ESC, Human body, Atrial fibrillation, NOAC, Thrombosis, Growth, ACC, XI, Pharmaceutical industry, Research, Bayer, Brain

The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2

Key Points: 
  • The underlying science of FXIa and Phase II PACIFIC data provide a foundation on which to advance asundexian forward into the OCEANIC Phase III program, one of the largest Phase III endeavors Bayer has undertaken.1-2
    The PACIFIC clinical trials form part of the broadest Phase IIb FXIa program in the world, involving more than 4,000 patients to date.3-5 The program is part of Bayers commitment to address unmet needs in a growing range of underserved cardiovascular patient communities.
  • Asundexian is a once-daily, oral investigational agent and has not been approved by any health authority for use in any country, for any indication.
  • Study to Gather Information About the Proper Dosing and Safety of the Oral FXIa Inhibitor BAY 2433334 in Patients Following an Acute Heart Attack (PACIFIC-AMI).
  • Safety of the oral factor XIa inhibitor asundexian compared with apixaban in patients with atrial fibrillation (PACIFIC-AF): a multicentre, randomised, double-blind, double-dummy, dose-finding phase 2 study.

Vejii Announces LOI to Acquire UK-Based Frozenly Limited Inc.

Retrieved on: 
Monday, May 9, 2022
Employment, NOAC, Social, Miray, OTC, Financial News, View, CEO, Risk, Forward-looking statement, Agriculture, Twitter, NASDAQ, Company, CSE, LOI, Woman, LinkedIn, News, Social media, THE, IPO, Intelligence, Blue Horizon, Food industry, COO, Population, Negotiation, EBITDA, Union, Letter, SPAC, Growth, Acquisition, Multimedia, United Kingdom, Venture capital financing, Data East USA, Inc. v. Epyx, Inc., Freedom, D2C, Intention, Canadian Securities Exchange, Restaurant, Retail, Security (finance), Financial services, Online shopping, Audit, Sebastiano, BC, Instagram, Facebook

Frozenly owns and operates MightyPlants.com , an e-commerce platform and marketplace that provides Direct to Consumer ("D2C") logistics and delivery for plant-based foods across the UK.

Key Points: 
  • Frozenly owns and operates MightyPlants.com , an e-commerce platform and marketplace that provides Direct to Consumer ("D2C") logistics and delivery for plant-based foods across the UK.
  • Frozenly has already established distribution in the UK market and formed relationships with top domestic and international brands.
  • Similar to Vejii's fulfilment model, Frozenly acts as an agent for brands, providing D2C order fulfilment services and sample distribution through its inventory consignment model.
  • "We are very excited to announce the signing of this LOI and the planned acquisition of Frozenly.

Fors Marsh Group CEO Announces Pledge to Conduct First Comprehensive Multiyear Public Opinion Survey on Attitudes about Substance Use Disorder at Conference, Joining Former President Bill Clinton as one of the Keynote Speakers; Shares Results of Initial N

Retrieved on: 
Monday, September 27, 2021
FMG, Adoption, Policy, Diagnosis, Garthwaite, Health, White House, NOAC, Conference, WPP, GRI, CDC, SUD, CEO, Happiness, Gaps, Knowledge, Awareness, Centers for Disease Control and Prevention, Disease, OUD, Center, Research, AmeriCorps, History, Organization, Fentanyl, Office of National Drug Control Policy, Health insurance, Management, Risk management

FMG conducted a brief survey in September to help inform the development of the multiyear effort.

Key Points: 
  • FMG conducted a brief survey in September to help inform the development of the multiyear effort.
  • The survey was among a nationally representative sample of 1,000 Americansto measure attitudes about SUD.
  • The initial results found that:
    81% agreed that most employers would be cautious of hiring someone who has been treated for SUD.
  • As a B Corporation, itgoverns from a set of values and policies that compound the positive impact for its employees, clients, and partners.

Thrombosis Research Institute (TRI) Shares Six New GARFIELD-AF And RIVER Real-world Data Analyses At ESC Congress 2021

Retrieved on: 
Monday, August 30, 2021
People, Congress, Blood, United States Preventive Services Task Force, Science, Task force, Observational study, European Union, AF, Teaching hospital, Rivaroxaban, European Society of Cardiology, Risk, Solution, Union, Tim Crow, Stroke, University, Associate, Thrombus, Diabetes, Chronic fatigue, Safety, Death, Adult, Recurrence, Patient, Thrombosis, Brain, Heart failure, Atrial fibrillation, Center, Incidence, Diagnosis, United, Ventricular fibrillation, VKA, Mortality, Population, TRI, Database, Physician, Prevalence, Warfarin, ESC, NOAC, Pharmaceutical industry, Medicine, Canal, Liquor, Medical imaging, Hospital

LONDON, Aug. 30, 2021 /PRNewswire/ -- The Thrombosis Research Institute (TRI) has six atrial fibrillation e-posters – four from the GARFIELD-AF Registry and two from the RIVER Registry – at the European Society of Cardiology (ESC) Congress 2021, which is taking place virtually from 27th to 30thAugust 2021.

Key Points: 
  • "We are delighted once again to have a strong showing at ESC Congress 2021," said Rt.
  • One of the RIVER posters looks at dosing, and shines a light on the issue of non-recommended dosing in patients based on renal function.
  • All of the TRI e-posters are available for registered participants to view on the ESC Congress 2021 Research Gateway platform at any time 'on demand'.
  • Our pioneering research programme, across medical disciplines and across the world, continues to provide breakthrough solutions in thrombosis.

Thrombosis Research Institute (TRI) Shares Six New GARFIELD-AF And RIVER Real-world Data Analyses At ESC Congress 2021

Retrieved on: 
Monday, August 30, 2021
People, Congress, Blood, United States Preventive Services Task Force, Science, Task force, Observational study, European Union, AF, Teaching hospital, Rivaroxaban, European Society of Cardiology, Risk, Solution, Union, Tim Crow, Stroke, University, Associate, Thrombus, Diabetes, Chronic fatigue, Safety, Death, Adult, Recurrence, Patient, Thrombosis, Brain, Heart failure, Atrial fibrillation, Center, Incidence, Diagnosis, United, Ventricular fibrillation, VKA, Mortality, Population, TRI, Database, Physician, Prevalence, Warfarin, ESC, NOAC, Pharmaceutical industry, Medicine, Canal, Liquor, Medical imaging, Hospital

LONDON, Aug. 30, 2021 /PRNewswire/ -- The Thrombosis Research Institute (TRI) has six atrial fibrillation e-posters – four from the GARFIELD-AF Registry and two from the RIVER Registry – at the European Society of Cardiology (ESC) Congress 2021, which is taking place virtually from 27th to 30thAugust 2021.

Key Points: 
  • "We are delighted once again to have a strong showing at ESC Congress 2021," said Rt.
  • One of the RIVER posters looks at dosing, and shines a light on the issue of non-recommended dosing in patients based on renal function.
  • All of the TRI e-posters are available for registered participants to view on the ESC Congress 2021 Research Gateway platform at any time 'on demand'.
  • Our pioneering research programme, across medical disciplines and across the world, continues to provide breakthrough solutions in thrombosis.

Global Anticoagulants Market 2020-2025 by Drug Class, Route of Administration, Geography with Impact of Covid-19 & Ansoff's Analysis - ResearchAndMarkets.com

Retrieved on: 
Wednesday, October 28, 2020
Pharmaceutical, Health, Cardiology, Anticoagulant, NOAC

The "Global Anticoagulants Market 2020-2025 by Drug Class, Route of Administration, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anticoagulants Market 2020-2025 by Drug Class, Route of Administration, Geography and Impact of Covid-19 with Ansoff's Analysis" report has been added to ResearchAndMarkets.com's offering.
  • Due to the increasing prevalence of various cardiovascular diseases coupled with the growing adoption of novel oral anticoagulants (NOACs), there has been a substantial rise in the market for anticoagulants.
  • The report offers a comprehensive evaluation of the Global Anticoagulants Market.
  • The report also contains a competitive analysis using Competitive Quadrant, the analyst's Proprietary competitive positioning tool.

Global Anticoagulants (Xarelto, Eliquis, Pradaxa, Savaysa) Market 2019-2023

Retrieved on: 
Wednesday, July 31, 2019
Anticoagulant, NOAC

DUBLIN, July 31, 2019 /PRNewswire/ -- The "Global Anticoagulants Market: Size, Trends & Forecasts (2019-2023 Edition)" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • DUBLIN, July 31, 2019 /PRNewswire/ -- The "Global Anticoagulants Market: Size, Trends & Forecasts (2019-2023 Edition)" report has been added to ResearchAndMarkets.com's offering.
  • Global Anticoagulants Market (2019-2023 Edition) provides an in-depth analysis of the global anticoagulants market with description of market size and growth.
  • The global anticoagulants market has increased over the years and is expected to grow in the next four years i.e.
  • The global anticoagulants market is supported by various growth drivers such as growing aging population, rising prevalence of coagulant disorders, increasing demand for NOACs, rising awareness about anticoagulants, etc.